drugset / Trial / NCT00406146

Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

NCT00406146

RandomizedParallel-groupSingle-blindTreatment

Summary

Artemisinin combination therapies (ACT) are currently recommended for malaria treatment. Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly adopted of the recommended ACT regimens. In Ghana, A+A is the current first-line antimalarial treatment in Ghana, but there has been 1 efficacy report of this regimen in Ghana till date. Moreover, the safety of repeated treatments with ACT has been little studied. This study aims to evaluate the efficacy of A+A vs. A-L, as well as the safety of repeated treatments of these regimens in a longitudinal trial in which recruited children will be followed up for 1 year.

Timeline

Start
2004-10
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Artemether Small molecule
Subject Artesunate Small molecule
Subject amodiaquine Other / unclassified
Subject lumefantrine Small molecule

Indications